We are live on ! Find out more
TAM

TFG Asset Management Portfolio holdings

AUM $635M
1-Year Est. Return 28.07%
This Fund
S&P 500
This Quarter Est. Return
+8.32%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$748M
AUM Growth
+$127M
Cap. Flow
-$123M
Cap. Flow %
-16.41%
Top 10 Hldgs %
83.35%
Holding
46
New
9
Increased
13
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$38.2M
2
MBX
MBX Biosciences
MBX
+$2.38M
3
ALKS icon
Alkermes
ALKS
+$2.09M
4
ABVX
Abivax
ABVX
+$1.84M
5
ARWR icon
Arrowhead Research
ARWR
+$1.8M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$6.15M
2
RLAY icon
Relay Therapeutics
RLAY
+$1.81M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.78M
4
ANNX icon
Annexon
ANNX
+$1.73M
5
KROS icon
Keros Therapeutics
KROS
+$1.26M

Sector Composition

Rank Sector Weight
1 Miscellaneous 45.42%
2 Technology 37.58%
3 Healthcare 11.03%
4 Energy 5.54%
5 Materials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$9.4B
$227M 30.33%
16,950,000
+3,227,756
+24% +$38.2M
HYG icon
2
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.6B
$59M 7.89%
726,900
-95,100
-12% -$7.66M
KGEI
3
Kolibri Global Energy
KGEI
$209M
$39.2M 5.24%
7,070,568
+1,711
+0% +$9.96K
LYFT icon
4
Lyft
LYFT
$6.7B
$22M 2.94%
1,000,000
– –
CXM icon
5
Sprinklr
CXM
$1.91B
$17M 2.27%
2,200,000
– –
AUTL
6
Autolus Therapeutics
AUTL
$623M
$15.5M 2.07%
9,500,000
– –
WK icon
7
Workiva
WK
$4.31B
$12.9M 1.73%
150,000
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$3.07B
$7.85M 1.05%
303,600
-12,550
-4% -$291K
TARS icon
9
Tarsus Pharmaceuticals
TARS
$3.15B
$7.43M 0.99%
125,000
-125,000
-50% -$6.15M
ANNX icon
10
Annexon
ANNX
$942M
$6.44M 0.86%
2,112,455
-697,545
-25% -$1.73M
HYG icon
11
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.6B
$5.92M 0.79%
72,961
+4,301
+6% +$347K
AXSM icon
12
Axsome Therapeutics
AXSM
$10.4B
$5.64M 0.75%
46,456
+4,925
+12% +$555K
PHVS icon
13
Pharvaris
PHVS
$2.48B
$4.86M 0.65%
194,612
+6,512
+3% +$144K
SRRK icon
14
Scholar Rock
SRRK
$7.04B
$4.39M 0.59%
117,882
+14,400
+14% +$504K
TECX
15
Tectonic Therapeutic
TECX
$696M
$3.82M 0.51%
243,728
+14,896
+7% +$307K
AMLX icon
16
Amylyx Pharmaceuticals
AMLX
$3.87B
$3.51M 0.47%
258,242
+39,492
+18% +$372K
MBX
17
MBX Biosciences
MBX
$3.03B
$3.11M 0.42%
+177,840
New +$2.38M
IMVT icon
18
Immunovant
IMVT
$8.51B
$3.04M 0.41%
188,379
+40,562
+27% +$657K
DYN icon
19
Dyne Therapeutics
DYN
$4.68B
$2.82M 0.38%
223,181
+84,806
+61% +$967K
ARWR icon
20
Arrowhead Research
ARWR
$12B
$2.82M 0.38%
+81,841
New +$1.8M
ALKS icon
21
Alkermes
ALKS
$7.95B
$2.69M 0.36%
89,612
+73,980
+473% +$2.09M
ABVX
22
Abivax
ABVX
$9.89B
$2.55M 0.34%
+30,000
New +$1.84M
SNOW icon
23
Snowflake
SNOW
$114B
$2.26M 0.3%
10,000
– –
ACAD icon
24
Acadia Pharmaceuticals
ACAD
$5.02B
$1.84M 0.25%
86,071
-75,325
-47% -$1.78M
HBM icon
25
Hudbay
HBM
$13B
$1.78M 0.24%
117,500
+10,500
+10% +$120K
1
2

Similar funds

GRR
Golden Reserve Retirement Dublin, Ohio $635M AUM 25.04% 1-Year Est. Return
GAM
Gould Asset Management Claremont, California $635M AUM 14.36% 1-Year Est. Return
MPIA
Mountain Pacific Investment Advisers Boise, Idaho $635M AUM 26.7% 1-Year Est. Return
AFG
Altiora Financial Group Lebanon, Ohio $634M AUM 13.93% 1-Year Est. Return
MWA
Martel Wealth Advisors Vancouver, Washington $636M AUM 12.74% 1-Year Est. Return
MCM
Maytus Capital Management New York $636M AUM 131.32% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
BAM
BOCHK Asset Management Hong Kong $634M AUM 64.99% 1-Year Est. Return

TFG Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, TFG Asset Management held 46 positions worth $748M, up 20% from $621M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

TFG Asset Management withdrew a net $123M in Q3 2025, closing 2 positions and reducing 9 holdings. Its most notable exit was Sociedad Química y Minera de Chile, an estimated $272K position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 45% of assets, up from 44% a quarter earlier, followed by Technology and Healthcare.

Against the trend, TFG Asset Management opened a new position in MBX Biosciences worth $3.11M.

  • TFG Asset Management's largest Q3 2025 buy was MBX Biosciences: 177,840 shares worth $3.11M.
  • TFG Asset Management added most to UiPath in Q3 2025, an estimated $38.2M increase.
  • TFG Asset Management's biggest Q3 2025 reduction was Tarsus Pharmaceuticals, cutting an estimated $6.15M.
  • TFG Asset Management fully exited Sociedad Química y Minera de Chile in Q3 2025, selling an estimated $272K.
  • TFG Asset Management's ten largest holdings make up 83% of its $748M portfolio in Q3 2025.
  • TFG Asset Management opened 9 new positions and closed 2 in Q3 2025.
  • TFG Asset Management's portfolio value rose 20% quarter-over-quarter to $748M.

Based on TFG Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.